Pages that link to "Q43565634"
Jump to navigation
Jump to search
The following pages link to Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients (Q43565634):
Displaying 18 items.
- Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both? (Q24804259) (← links)
- Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons (Q24816834) (← links)
- Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a review (Q26866784) (← links)
- Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins (Q28200554) (← links)
- Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review (Q28220294) (← links)
- Targeting Peroxisome Proliferator-Activated Receptors Using Thiazolidinediones: Strategy for Design of Novel Antidiabetic Drugs (Q33809886) (← links)
- Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study (Q34262967) (← links)
- Relationship and factors responsible for regulating fasting and post-challenge plasma glucose levels in the early stage development of type 2 diabetes mellitus. (Q34523674) (← links)
- Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients (Q34557349) (← links)
- Peroxisome Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions (Q36261125) (← links)
- Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention? (Q36411656) (← links)
- Long-term effects of peroxisome proliferator-activated receptor ligand bezafibrate on N-terminal pro-B type natriuretic peptide in patients with advanced functional capacity impairment (Q37103798) (← links)
- Potential Role of ANGPTL4 in the Cross Talk between Metabolism and Cancer through PPAR Signaling Pathway (Q37611286) (← links)
- Lipid-lowering therapies, glucose control and incident diabetes: evidence, mechanisms and clinical implications. (Q38222135) (← links)
- Combination therapy with PPARgamma and PPARalpha agonists increases glucose-stimulated insulin secretion in db/db mice (Q44391131) (← links)
- Effects of a novel selective peroxisome proliferator-activated receptor-α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance. (Q52722693) (← links)
- Prevention of Elevation in Plasma Triacylglycerol with High-Dose Bezafibrate Treatment Abolishes Insulin Resistance and Attenuates Glucose Intolerance Induced by Short-Term Treatment with Dexamethasone in Rats (Q59796553) (← links)
- The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development (Q90638915) (← links)